NewsRamp Psychedelics Podcast

NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Episodes

Global Psychedelic Week 2025: A Worldwide Exploration of Psychedelic Therapies and Perspectives

October 20, 2025 • 2 mins
Global Psychedelic Week 2025 will feature 130 global speakers and 100 in-person events worldwide, including discussions on psychedelic therapies in crisis zones, evidence-based approaches in psychedelic enterprises, indigenous perspectives, women in psychedelics, and the role of psychedelics in addressing climate change. The conference aims to decentralize the conversation and prioritize inclusivity and community, with early bird r...
Mark as Played

Advancements in Preservative-Free Ketamine Therapies by NRx Pharmaceuticals

October 17, 2025 • 1 min
NRx Pharmaceuticals is making significant progress in developing preservative-free ketamine-based therapies through two different pathways, including KETAFREE and NRX-100. With FDA approval to remove benzethonium chloride for KETAFREE and Fast Track Designation for NRX-100, the company is demonstrating a commitment to innovative treatments for mental health disorders. CEO Dr. Jonathan Javitt recently highlighted these advancements ...
Mark as Played

FDA Approval Secured for Preservative-Free Ketamine: NRx Pharmaceuticals Expands Market Opportunity

October 7, 2025 • 1 min
NRx Pharmaceuticals Inc. has received FDA approval for a Suitability Petition, allowing them to re-file for their preservative-free ketamine product. This aligns with NRx's focus on developing treatments for suicidal depression and PTSD, while tapping into the growing demand for safer pharmaceutical options in the U.S. market.
Mark as Played

Uniting the World: Global Psychedelic Week 2025

October 2, 2025 • 1 min
Global Psychedelic Week 2025, the first distributed psychedelic conference, will bring together 5,000 people from 100 countries with 100+ speakers like Rick Doblin and Robin Carhart-Harris. With events in nearly 60 cities and partnerships with 70+ organizations, GPW aims to promote global dialogue and action on psychedelics. Early bird registration is now open at www.globalpsychedelicweek.com.
Mark as Played

Advancements and Milestones in Neuropsychiatry Drug Development by Cybin Inc.

September 24, 2025 • 2 mins
Cybin Inc. provided updates on its drug discovery platforms, highlighting key milestones such as upcoming Phase 2 and Phase 3 program data releases for anxiety and depression disorders, along with a strategic manufacturing partnership. The Company's intellectual property portfolio is secured until 2041, with promising response rates and FDA Breakthrough Therapy Designation for its CYB003 program.
Mark as Played

Fireside Chat at TD Cowen's Summit with Cybin Inc. Executives

September 12, 2025 • 2 mins
Cybin Inc.'s Chief Medical Officer and Chief Business Officer will be participating in a fireside chat at an upcoming summit to discuss the company's focus on developing innovative treatment options for mental health conditions, including their ongoing Phase 3 and Phase 2 studies for major depressive disorder and generalized anxiety disorder, respectively. Established in 2019, Cybin is a clinical-stage neuropsychiatry company with ...
Mark as Played

Advancements in Mental Health Treatments: NRx Pharmaceuticals and Cybin Inc. Acquisitions and Developments

September 9, 2025 • 2 mins
NRx Pharmaceuticals' subsidiary HOPE Therapeutics Inc. has acquired Dura Medical, a provider of interventional psychiatry services in Florida, expanding its network. Meanwhile, Cybin Inc. has completed enrollment in its Phase 2 study of CYB004 for Generalized Anxiety Disorder, with topline data expected in Q1 2026, aiming to address the needs of millions of Americans living with GAD.
Mark as Played

Cybin Inc. Chief Business Officer to Speak at H.C. Wainwright Conference

September 4, 2025 • 1 min
Cybin Inc., a neuropsychiatry company, will have their Chief Business Officer participating in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference to discuss their focus on developing new treatment options for mental health conditions, including CYB003 in Phase 3 studies for major depressive disorder and CYB004 in a Phase 2 study for generalized anxiety disorder. Established in 2019, Cybin is actively op...
Mark as Played

Fireside Chat with Cybin Inc.'s CMO at Cantor Global Healthcare Conference

September 3, 2025 • 1 min
Cybin Inc.'s Chief Medical Officer, Amir Inamdar, will be participating in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, discussing the company's focus on developing new treatment options for mental health conditions such as major depressive disorder and generalized anxiety disorder. The session will be webcast live and available for replay on Cybin's investor relations website. Founded in 2019, C...
Mark as Played

Leadership Changes and Treatment Advancements in Mental Health Companies

September 2, 2025 • 2 mins
Cybin Inc. appoints Eric So as Interim CEO following Doug Drysdale's resignation, focusing on advancing clinical pipeline for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. secures FDA Fast Track designation for IV ketamine formulation NRX-100 in treating suicidal depression, expanding its potential patient pool.
Mark as Played

Advancing Psilocybin Therapy: Psylutions Supports Rescheduling Efforts

August 28, 2025 • 2 mins
Psylutions, a pioneering cultivator and manufacturer of psilocybin in Colorado, praises the DEA's decision to advance a petition to reschedule psilocybin for scientific review by the U.S. Department of Health and Human Services. This move is seen as a significant stride towards mainstream acceptance of psychedelics in medicine, offering hope for patients in palliative care and Veterans with PTSD. Psylutions is poised to lead the ch...
Mark as Played

Empowering Growth for Ketamine & TMS Clinics: Strategic Partnership Announcement

August 27, 2025 • 2 mins
Ketamine Lead Gen partners with HealingMaps and Healing Health Alliance to support the growth of Ketamine & TMS clinics by providing patient education, digital marketing, and operational solutions. The collaboration aims to enhance clinic profitability and scalability through high-intent patient discovery, measurable marketing strategies, and exclusive benefits for clinic owners.
Mark as Played

Cybin Inc. Receives Approval for Phase 3 Study of CYB003 in Australia

August 27, 2025 • 2 mins
Cybin Inc. has been granted approval to start the EMBRACE Phase 3 study of CYB003 in Australia, marking a significant milestone in their development of new treatment options for mental health conditions. This study is part of Cybin's Phase 3 multinational program, PARADIGM, and focuses on major depressive disorder.
Mark as Played

NRx Pharmaceuticals Urges FDA to Ban Benzethonium Chloride from Ketamine Products

August 22, 2025 • 2 mins
NRx Pharmaceuticals, listed on NASDAQ as NRXP, has filed a Citizen Petition asking the FDA to prohibit the use of benzethonium chloride in ketamine products due to its toxic nature. The company has presented evidence supporting the safety and stability of their preservative-free ketamine, 'NRX-100', and is also seeking FDA approval for their oral NMDA-targeting drug, 'NRX-101'. Learn more about NRx Pharmaceuticals and stay updated ...
Mark as Played

Advancements in Incannex Healthcare Inc.: Positive Phase 2 Results and Strong Valuation Potential

August 21, 2025 • 2 mins
Stonegate Capital Partners' updated coverage on Incannex Healthcare Inc. highlights the positive Phase 2 study results of their IHL-42X asset, showing significant reduction in Apnoea-Hypopnoea Index. Patient-reported outcomes were also impressive, boosting IXHL's prospects for bringing IHL-42X to market. The company's financial position has improved through strategic financing, and other projects like PSX-001 and IHL-675A are progr...
Mark as Played

Cybin Inc. Reports Promising Results and Shareholder Meeting Summary

August 19, 2025 • 1 min
Cybin Inc., a neuropsychiatry company, discussed developments in innovative mental health treatments at their recent shareholder meeting, with a focus on promising data for CYB003 and CYB004. Shareholders representing nearly half of the company's common shares were present. Visit Cybin's newsroom for further details.
Mark as Played

Cybin Inc. Reports Q1 2025 Results and Progress in Depression and Anxiety Studies

August 14, 2025 • 2 mins
Cybin Inc., a clinical-stage neuropsychiatry company, shared its Q1 2025 results and updates on its Phase 3 Depression Program and Phase 2 Anxiety Study. The company has expanded its Phase 3 program for major depressive disorder and is close to completing enrollment for its anxiety study. With adequate funding, Cybin is poised to address the pressing need for improved mental health treatments.
Mark as Played

NRx Pharmaceuticals' HOPE Therapeutics(TM) Expands Network and Expertise with Acquisition of Dura Medical LLC

August 8, 2025 • 2 mins
NRx Pharmaceuticals' subsidiary HOPE Therapeutics(TM) has received regulatory clearance in Florida to acquire Dura Medical LLC, a clinic specializing in mental health and chronic pain treatment. This acquisition will enhance HOPE's presence in Florida and strengthen their capabilities in utilizing psychedelic medications and neuroplastic technologies to treat depression and PTSD. NRx Pharmaceuticals is also progressing with filing ...
Mark as Played

Cybin Inc. Receives European Approval for Phase 3 Study on CYB003 for Major Depressive Disorder

August 7, 2025 • 2 mins
Cybin Inc. has obtained approval to launch the EMBRACE Phase 3 study in Ireland, Poland, and Greece as part of their PARADIGM program. The study will evaluate the efficacy of CYB003, a proprietary deuterated psilocin analog, in treating Major Depressive Disorder by enrolling 330 participants across various international sites. Visit www.cybin.com for more information on Cybin and its innovative mental healthcare research pipeline.
Mark as Played

Revolutionizing Mental Healthcare: Cybin's CEO to Speak at Growth Conference

August 6, 2025 • 2 mins
Cybin Inc., a neuropsychiatry company, will have CEO Doug Drysdale participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Cybin is dedicated to developing new treatment options for mental health conditions, with ongoing studies on major depressive disorder and generalized anxiety disorder. A live webcast of the event will be available, showcasing Cybin's commitment to transforming mental healthcare.
Mark as Played

Popular Podcasts

    Stuff You Should Know

    Stuff You Should Know

    If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

    Dateline NBC

    Dateline NBC

    Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

    CrimeLess: Hillbilly Heist

    CrimeLess: Hillbilly Heist

    It’s 1996 in rural North Carolina, and an oddball crew makes history when they pull off America’s third largest cash heist. But it’s all downhill from there. Join host Johnny Knoxville as he unspools a wild and woolly tale about a group of regular ‘ol folks who risked it all for a chance at a better life. CrimeLess: Hillbilly Heist answers the question: what would you do with 17.3 million dollars? The answer includes diamond rings, mansions, velvet Elvis paintings, plus a run for the border, murder-for-hire-plots, and FBI busts.

    The Breakfast Club

    The Breakfast Club

    The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious, And Charlamagne Tha God!

    Crime Junkie

    Crime Junkie

    Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

Explore

iHeart

Live Radio

Podcasts

Artist Radio

Exclusives

News

Features

Events

Contests

Photos

Information

About

Advertise

Blog

Brand Guidelines

Contest Guidelines

Subscription Offers

Jobs

Get the App

Automotive

Home

Mobile

Wearables

© 2025 iHeartMedia, Inc.